Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study
Authors:
- 1 April 2013
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (4) , 354-362
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment FailureJournal of Clinical Oncology, 2011
- Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and MyelodysplasiaJournal of Clinical Oncology, 2010
- A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid TumorsClinical Cancer Research, 2009
- CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic CellsCancer Research, 2008
- Age and acute myeloid leukemiaBlood, 2006
- Trends in the Treatment of Acute Myeloid Leukaemia in the ElderlyDrugs & Aging, 2005
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.2003
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002
- Amino acid limitation regulates CHOP expression through a specific pathway independent of the unfolded protein responseFEBS Letters, 1999